Cresco Labs (OTC: CRLBF) reported second-quarter fiscal year 2026 revenue of $173 million, marking a 15% sequential increase from the prior quarter. The cannabis operator generated $40 million in adjusted EBITDA, reflecting a 20% sequential rise and demonstrating operating leverage as it expands its footprint in key markets.

The growth was driven by the contribution of nine Pennsylvania dispensaries acquired under a managed service agreement and new Sunnyside locations in Ohio. Retail revenue climbed 18% sequentially to $121 million, while net wholesale revenue increased 7% to $52 million. Management noted that organic growth contributed 4% to the sequential revenue increase, excluding the impact of new acquisitions.

Financial Performance Highlights

The company’s adjusted gross profit reached $89 million, representing a 52% margin, which exceeded the high end of its guidance range. This margin expansion was attributed to wholesale product improvements in Massachusetts and Ohio, partially offset by a mix shift toward lower-margin volume in Michigan.

Operational Drivers and Market Position

Cresco Labs emphasized its strategy of deepening market presence through both organic execution and disciplined mergers and acquisitions. In Pennsylvania, the company holds the number one branded share at 16%. The recently acquired stores have already seen an 11% increase in gross profit dollars compared to pre-acquisition baselines, without rebranding. Management indicated that further value unlock is expected once the Sunnyside brand is fully deployed after state approval closes.

In Ohio, Sunnyside secured the number two retail share position, with new dispensaries outperforming peers due to careful site selection. Meanwhile, in Illinois, despite intensified competition, Cresco maintained the number one position in flower, concentrates, and edibles, holding revenue per gram steady against broader market compression.

Leadership Transition and Strategic Outlook

Chief Financial Officer Sharon Schuller announced her decision to step down from her role. A transition plan is in place as the company searches for a successor. CEO Charles Bachtell highlighted the potential impact of federal cannabis reform, specifically rescheduling, which could remove the punitive Section 280E tax burden. This regulatory shift is expected to improve net income and strengthen balance sheets, potentially facilitating U.S. exchange listings and improved access to capital.

Looking ahead to Q3FY26, management expects net revenue to remain roughly in line with Q2 as ramping acquired stores offset price compression. Gross margins are guided to the high 40s to 50%, while adjusted EBITDA margins are projected at approximately 20%.

What the Numbers Show

A divergence between revenue growth and EBITDA growth highlights significant operating leverage. While revenue rose 15% sequentially, adjusted EBITDA increased by 20%. This indicates that incremental revenue is converting to profit at a higher rate than the base business, likely driven by productivity gains from AI deployment and cost discipline that absorbed growth-related expenses in SG&A.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) has filed its Management Information Circular for an annual general and special meeting scheduled for October 30, 2026. The company is seeking shareholder approval for three key resolutions designed to streamline its capital structure and governance in preparation for a potential listing on a senior U.S. exchange.

The proposals include the creation of a new parent company, TopCo, through a share exchange; the subsequent redomicile of TopCo from British Columbia to Delaware; and an extension of the sunset date for the company’s multiple voting shares (MVS). Charles Bachtell, CEO of Cresco Labs, stated that these measures aim to lower administrative costs and complexity while positioning the firm for U.S. capital markets access.

Proposed structural changes

The board has unanimously recommended that shareholders vote in favor of each resolution. The specific measures under consideration are:

1. Share Exchange Resolution: This involves creating TopCo as the new publicly listed entity. Cresco Labs securities would be exchanged for TopCo securities on a one-for-one basis, leaving shareholders’ relative voting and economic rights unchanged. The board retains discretion to effect a reverse share split if necessary to meet U.S. exchange listing requirements.

2. Redomicile to Delaware: If approved, TopCo would move its domicile from British Columbia to Delaware. This step aligns the corporate structure with operational jurisdictions and makes it more familiar to U.S. investors. The resolution also provides for the adoption of a new long-term equity incentive plan tailored for a U.S.-domiciled issuer. The board may implement this change at any time on or before December 31, 2027.

3. MVS Sunset Extension: The proposal seeks to amend the terms of the MVS by extending the sunset date from the first anniversary to the third anniversary of a U.S. listing. This extension is intended to support strategic continuity during the redomicile and listing process, after which the multiple voting shares would convert automatically.

Meeting logistics and other agenda items

In addition to the special resolutions, shareholders will review financial statements for the years ended December 31, 2025 and December 31, 2024. Other annual business items include setting the number of directors at seven, electing directors, and reappointing Baker Tilly US, LLP as the independent auditor.

The meeting will be held via live audio webcast at 12:00 pm Central Daylight Time on Friday, October 30, 2026. Shareholders of record as of the close of business on September 15, 2026 are entitled to vote. Proxies must be received by 12:00 pm Central Daylight Time on Wednesday, October 28, 2026.

Regulatory context

The company emphasized that this announcement does not constitute an offer to sell securities or a solicitation of any vote in any jurisdiction where such action would contravene applicable law. The full text of the circular and related materials are available on SEDAR+ and EDGAR.